Aberdeen Group plc lifted its holdings in uniQure N.V. (NASDAQ:QURE – Free Report) by 25.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,678,640 shares of the biotechnology company’s stock after purchasing an additional 738,897 shares during the quarter. Aberdeen Group plc owned about 5.91% of uniQure worth $88,030,000 as of its most recent SEC filing.
A number of other large investors have also bought and sold shares of QURE. Swiss National Bank acquired a new position in uniQure in the 2nd quarter worth $1,080,000. Sanders Morris Harris LLC acquired a new stake in shares of uniQure in the 3rd quarter valued at about $5,081,000. Vanguard Group Inc. lifted its holdings in shares of uniQure by 15.7% in the third quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after purchasing an additional 152,417 shares in the last quarter. Voss Capital LP bought a new stake in shares of uniQure in the second quarter valued at about $1,742,000. Finally, Quinn Opportunity Partners LLC acquired a new position in shares of uniQure during the third quarter worth about $6,281,000. 78.83% of the stock is owned by institutional investors.
uniQure Price Performance
Shares of NASDAQ:QURE opened at $17.16 on Friday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $1.07 billion, a PE ratio of -4.97 and a beta of 0.75. The firm has a 50 day moving average of $19.26 and a 200-day moving average of $29.40. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50.
Insider Buying and Selling at uniQure
In related news, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company’s stock, valued at approximately $796,260.04. The trade was a 44.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This represents a 2.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 81,399 shares of company stock worth $1,527,645 over the last quarter. 4.79% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the company. TD Cowen reiterated a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research note on Tuesday, March 3rd. Stifel Nicolaus set a $14.00 price objective on shares of uniQure in a report on Monday, March 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, uniQure has an average rating of “Moderate Buy” and a consensus price target of $42.75.
Check Out Our Latest Research Report on QURE
Key Headlines Impacting uniQure
Here are the key news stories impacting uniQure this week:
- Negative Sentiment: Hagens Berman updates its probe into uniQure following public FDA criticism and allegations that data were distorted — a development that amplifies regulatory and litigation risk. QURE ALERT: Hagens Berman Updates uniQure (QURE) Probe After FDA Criticism; April 13 Deadline Nears
- Negative Sentiment: Hagens Berman issues a separate shareholder alert alleging public FDA rebukes and “distorted” data, reinforcing the narrative of potential securities claims and reputational damage. QURE SHAREHOLDER ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data
- Negative Sentiment: Robbins LLP reminds investors of a class action covering purchases from Sept. 24–Oct. 31, 2025, signaling additional potential plaintiffs and litigation costs. uniQure N.V. Class Action Reminder – Robbins LLP Encourages QURE Stockholders to Contact the Firm for Information About Their Rights
- Negative Sentiment: ClaimsFiler warns investors of the April 13 deadline to apply for lead‑plaintiff status in the securities class action — a near‑term administrative catalyst that may increase filings. uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. – QURE
- Negative Sentiment: Rosen Law Firm issues a deadline reminder for purchasers in the Sept.–Oct. 2025 class period, reinforcing the expectation of continued legal activity. UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action – QURE
- Negative Sentiment: Bragar Eagel & Squire and other firms (Pomerantz, Schall Law Firm, etc.) are soliciting large‑loss investors and offering to pursue lead‑plaintiff status, indicating multiple firms are competing to litigate — a sign of escalating legal attention. UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13th
- Negative Sentiment: Pomerantz and The Schall Law Firm similarly remind investors of the class action and filing deadlines, adding to the chorus of litigation notices that can increase legal expenses and distract management. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
- Negative Sentiment: Local/regional outlets republished firm notices (Rosen, Bragar, Rosen deadline stories), increasing visibility of the litigation and potentially pressuring retail holders to sell. UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure …
uniQure Profile
uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.
Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.
See Also
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
